GAT-1 embodies an important pharmaco-therapeutic target and loss-of-function mutations in the GAT-1 gene have latterly been associated with epilepsy, intellectual disability and autism (Goodspeed et al., 2020; Mattison et al., 2018). Here, SLC6A1 is linked to epilepsy.